Sanguina Secures Investment from Georgia Innovation Investor Syndicate to Advance Medtech Commercialization

New collaboration with EBFI, Invest Georgia, and Georgia Tech highlights the power of Georgia-based research, investors, and startups working together to bring university innovation from bench to market.

PEACHTREE CORNERS, GA — March 31, 2026 — Sanguina, Inc., an Atlanta-based blood health technology company developing AI-powered tools for blood health monitoring, today announced a new round of strategic investment from Georgia-based innovation partners, including the Emory BioFoundry Institute (EBFI), Invest Georgia, and Georgia Tech Research Impact Fund. The investment strengthens a uniquely Georgia-based collaboration to accelerate the commercialization of university-developed technology and expand access to noninvasive blood health monitoring through Sanguina’s smartphone application.

Founded on intellectual property developed through leading Georgia research institutions, Sanguina represents a powerful example of how academic innovation can move from the laboratory bench to real-world healthcare solutions. The company’s flagship technology, Ruby, is an AI-powered smartphone application that analyzes a simple fingernail photo to provide insights into blood health and help users monitor indicators associated with iron deficiency and anemia.

This latest investment highlights an ongoing effort to form a power syndicate partnership within Georgia’s innovation ecosystem: university-generated intellectual property, startup company formation, and Georgia-based investors working together to bring breakthrough healthcare technologies to market while generating meaningful value to all stakeholders.

Georgia is increasingly recognized as a national hub for biomedical innovation, anchored by world-class institutions such as the Emory and Georgia Tech joint Department of Biomedical Engineering — ranked #1 undergraduate and #2 graduate program in the United States — as well as Emory Healthcare, the leading hospital system in metro Atlanta and across Georgia. The state is also home to the nation’s top-ranked undergraduate and master’s nursing programs at Emory University. Despite these strengths, early-stage medtech companies have historically faced limited access to venture capital funding and networks, making partnerships like this an innovative starting point to enable the translation of technologies from research to real-world impact in Georgia’s fertile ground and ultimately put the region’s innovation pipeline on investors' maps.

Moreover, by supporting companies like Sanguina, Georgia-based investors and institutions are helping ensure that breakthrough technologies developed in the state have the opportunity to grow, scale, and generate economic impact locally.

The partnership reinforces a broader effort to strengthen Georgia’s role in the national medtech landscape by fostering deeper collaboration between research institutions, startups, and capital providers.

About Sanguina, Inc.

Sanguina is a biotechnology and digital health company transforming biological markers into scalable blood health assessment tools through patented digital technology. Its AI-powered smartphone application analyzes biological characteristics of fingernails to derive blood health biomarkers, enabling noninvasive monitoring supported by published clinical data. Sanguina partners with healthcare systems, insurers, and industry to generate biomarker-driven datasets that help predict medical events and disease progression. With millions of proprietary biological data points collected globally, from low-resource settings to patient homes, Sanguina is building one of the world’s largest digital datasets for blood health and redefining accessible monitoring through biotechnology innovation.